Drugs / Trifluridine/tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07142421 | Aug 2025 → Aug 2027 expected | esophageal squamous cell carcinoma | First Affiliated Hospital of Zhejiang University | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/tipiracil | “Suyuan (trifluridine/tipiracil) is a new oral fluoropyrimidine drug composed of trifluridine (a cytotoxic component) and tipiracil (a synergist that inhibits the metabolic...” NCT07142421 ↗ |
| Known as | Suyuan | “Suyuan (trifluridine/tipiracil) is a new oral fluoropyrimidine drug composed of trifluridine (a cytotoxic component) and tipiracil (a synergist that inhibits the metabolic...” NCT07142421 ↗ |
| Action | Inhibit | “tipiracil (a synergist that inhibits the metabolic enzyme TP)” NCT07142421 ↗ |
| Modality | Small molecule | “Suyuan (trifluridine/tipiracil) is a new oral fluoropyrimidine drug composed of trifluridine (a cytotoxic component) and tipiracil (a synergist that inhibits the metabolic...” NCT07142421 ↗ |
| Route | Oral | “Suyuan (trifluridine/tipiracil) is a new oral fluoropyrimidine drug composed of trifluridine (a cytotoxic component) and tipiracil (a synergist that inhibits the metabolic...” NCT07142421 ↗ |